Making the Right Call: Biomarker Testing and Targeting in NSCLC: Treating Acquired Resistance and Evaluating Next-generation Therapies

The evolution of the non-small cell lung cancer (NSCLC) treatment landscape and the discovery of predictive biomarkers that can be targeted by novel therapies or combinations is facilitating more individualized treatment. However, drug resistance plays a major role in therapeutic failure and clinicians must stay alert to the current and emerging treatment options to provide optimal care. Are you ready to test your skills amongst your colleagues? Join us for Part 2 of this question and answer based educational activity Treating Acquired Resistance and Evaluating Next-generation Therapies where our oncology experts will:

• Discuss treatment selection for patients with acquired resistance to targeted therapy
• Present the latest clinical evidence on new and emerging targeted therapies
• Provide strategies to promote patient engagement in their care